Vaxcyte, Inc. (PCVX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Vaxcyte, Inc. (PCVX)

Company Performance

Current Price

as of Oct 16, 2024

$117.93

P/E Ratio

N/A

Market Cap

$14.36B

Description

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Metrics

Overview

HQSan Carlos, CA
SectorHealth Technology
IndustryBiotechnology
TickerPCVX
Price$117.93+2.11%

Trading Information

Market Cap$14.36B
Float96.14%
Average Daily Volume (1m)745,036
Average Daily Volume (3m)932,438
EPS-$4.76

Company

RevenueN/A
Rev Growth (1yr)N/A
Net Income-$128.70M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$149.50M

EV$7.43B
EV/RevenueN/A
P/EN/A
P/SN/A
P/B6.57

Documents

Earnings Calls

Earnings Report 2023Q4

Earnings Report (2023-02-27)

Factset Street Account

Vaxcyte reports Q3 EPS ($0.91) vs FactSet ($0.84) [8 est, ($0.96)-(0.73)] ($48.36, 0.00) (2023-11-06T21:04:45Z)

Vaxcyte exercises option and enters into manufacturing rights agreement with Sutro Biopharma to obtain control over manufacturing and development of cell-free extract for vaccine candidates ($50.17, 0.00) (2023-11-27T21:02:03Z)

Vaxcyte doses first participants in Phase 1/2 clinical study evaluating VAX-31 for the prevention of invasive pneumococcal disease in adults ($50.60, 0.00) (2023-11-09T13:35:07Z)